Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Golidocitinib-based therapy in relapsed/refractory mycosis fungoides and Sézary syndrome: A real-world retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

TDTianling Ding

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows golidocitinib improves response rates in relapsed mycosis fungoides and Sézary syndrome, suggesting new treatment pathways.

Key Points

  • Evaluate the efficacy and safety of golidocitinib therapy in real-world patients with relapsed mycosis fungoides and Sézary syndrome.
  • Retrospective analysis of 10 patients treated with golidocitinib-based therapy.
  • Golidocitinib was administered at 150 mg daily with optional dose reduction.
  • Combination therapy included brentuximab vedotin in 90% of cases.
  • Best overall and skin response rates were 80%, with 8 out of 10 patients showing improvement.
  • Significant elevation of IFN-γ levels post-treatment observed despite immunosuppressive effects.
  • Treatment-related adverse events occurred in 60%, with cytomegalovirus infection noted in 50%.

Cite This Study

Tianling Ding (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e0https://doi.org/10.1182/blood-2025-8079
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia2025
  2. 2Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial2025 · 1 citations
  3. 3Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study2025 · 1 citations
  4. 4Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib2025
  5. 5Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025